This is the authors' abstract. We don't add key points for this paper.
Objectives: Analysis of peripheral blood cell counts are important in the workup of patients with suspected Corona virus disease 2019 . Blood cell counts are usually analyzed on large cell counters that require transport of the samples. Point-of-care (POC) testing reduces the test-turnaround times. The aim of the present study was to evaluate if the HemoScreen instrument could be used for point of care testing of blood samples from COVID-19 patients. Methods: We compared CBC results from 49 patients with COVID-19 infections analyzed with HemoScreen and Sysmex XN-9000. Results: There were strong correlations between the results obtained with Sysmex XN-9000 and HemoScreen according to Deming correlations for White Blood Cells (WBC): WBCHemoScreen = 0.944 * WBCSysmex -0.093; r 2 = 0.988, Neutrophils: NeutrophilsHemoScreen = 1.029 * NeutrophilsSysmex + 0.090; r 2 = 0.957, Lymphocytes: LymphocytesHemoScreen = 0.944 * LymphocytesSysmex -0.107; r 2 = 0.964, Platelets (PLT): PLTHemoScreen = 1.056* PLTSysmex + 9.468; r 2 = 0.988, and Red blood cells (RBC) RBCHemoScreen = 0.955 * RBCSysmex -0.003; r 2 = 0.991. Conclusions: The HemoScreen instrument provided fast and accurate test results when analyzing blood samples from COVID-19 patients. This instrument can be used in settings where the transport time to the central laboratory from remote locations such as field hospitals can be long.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Karawajczyk et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: